After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Cerevel Therapeutics Holdings Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Cerevel Therapeutics Holdings Inc is $7.45B. A total of 1.69 million shares were traded on the day, compared to an average of 3.00M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, CERE has seen 1 BUY and 1 SELL insider trades, representing the acquisition of 8,000 and the disposition of 8,000 shares. Over the last 12 months, there were 24 BUYs and 18 SELLs from insiders. Insiders purchased 12,405,204 shares during that period but sold 1,505,279.
In the most recent transaction, COLES N ANTHONY sold 2,506 shares of CERE for 41.54 per share on Feb 07. After the transaction, the Director now owns 15,638 company shares. In a previous transaction on Feb 07, Renger John sold 2,161 shares at 41.54 per share. CERE shares that Chief Scientific Officer owns now total 6,370.
Among the insiders who sold shares, COLES N ANTHONY disposed of 50,000 shares on Jan 02 at a per-share price of $42.24. This resulted in the Director holding 2,704 shares of CERE after the transaction. In another insider transaction, Sanchez Ramiro sold 10,000 shares at $42.47 per share on Dec 26. Company shares held by the Chief Medical Officer now total 14,673.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, CERE has a high of $43.59 and a low of $19.59.
As of this writing, CERE has an earnings estimate of -$0.59 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.53 per share and a lower estimate of -$0.67. The company reported an EPS of -$0.61 in the last quarter, which was 3.20% higher than expectations of -$0.63.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. CERE’s latest balance sheet shows that the firm has $565.69M in Cash & Short Term Investments as of fiscal 2021. There were $36.55M in debt and $42.54M in liabilities at the time. Its Book Value Per Share was $3.71, while its Total Shareholder’s Equity was $578.73M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CERE is Buy with a score of 3.36.
